Pabgraminone C
Pabgraminone C (IM502) is a Fungal metabolite and PI3Kγ inhibitor with an IC50 of 61.7 nM against PI3Kγ. Pabgraminone C shifts the STAT signaling pathway in cells from an immunosuppressive STAT3/STAT6-dominant profile to an immunostimulatory STAT1/STAT2-dominant profile, driving cells toward a pro-inflammatory phenotype. Pabgraminone C reprograms cells from an immunosuppressive state to an immunostimulatory state, reversing their suppressive effect on anti-tumor immunity. Pabgraminone C inhibits established tumor growth and metastasis across multiple cancer types. Pabgraminone C overcomes resistance to PD-1 checkpoint blockade strategies. Pabgraminone C can be used in research related to liver cancer, melanoma, and colorectal cancer.
For research use only. We do not sell to patients.
- CAS No.: 3061276-55-6
- Formula: C16H20O4
- Molecular Weight:276.33
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Endogenous Metabolite Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
PI3Kγ 61.7 nM (IC50) |
PI3Kα 252.3 nM (IC50) |
PI3Kβ 532.5 nM (IC50) |
PI3Kδ 407.9 nM (IC50) |
STAT3 |
STAT6 |
STAT1 |
STAT2 |
Fungal Metabolite |
In Vitro
Pabgraminone C (0-1500 nM; 30 min) potently inhibits the activity of purified PI3Kγ enzyme, with an IC50 of 61.7 nM[1].
Pabgraminone C (10 μM; 24 h) reverses the immunosuppressive effect of monocyte-derived macrophages polarized by TCM, and promotes CD8+ T cell proliferation and cytokine production[1].
Pabgraminone C (10 μM; 6 h) alleviates oxidative stress in mouse TCM-polarized macrophages, reduces the levels of ROS and lipid peroxidation, and restores mitochondrial function and antioxidant levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human monocyte-derived macrophages and human CD8+ T cells
-
Concentration:10 μM
-
Incubation Time:24 h (macrophage pre-treatment)
-
Result:Restored human CD8+ T cell proliferation and increased secretion of IFNγ and IL-2.
In Vivo
Pabgraminone C (6 mg/kg; intravenous injection; administered twice on day 0 and day 3 after tumor inoculation) inhibits experimental melanoma lung metastasis by more than 50% in immunocompetent mice[1].
Pabgraminone C (1.5 mg/kg; intravenous injection) enhances the antitumor efficacy of Sorafenib (HY-10201) in orthotopic liver tumors, and exhibits superior inhibitory effects on tumor growth and metastasis compared with either single-agent treatment[1].
Pabgraminone C (1.5 mg/kg; intravenous injection; administered once every 2 days for a total of 4 doses starting when the tumor volume reaches ~17 mm2) does not inhibit the growth of subcutaneous MC38 tumors in immunodeficient Rag2-/- mice, which confirms that its antitumor activity is immune-mediated[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J WT (6-8 weeks old); Balb/C WT[1]
-
Dosage:1.5 mg/kg
-
Administration:i.v.; 4 doses every 2 days starting when tumors reached ~17 mm2
-
Result:Significantly reduced mean tumor growth in Hepa1-6BL hepatocellular carcinoma, B16F10 melanoma, CT26 colorectal carcinoma, and MC38 colorectal carcinoma subcutaneous models compared to control.
Achieved comparable efficacy to first-line chemotherapy FOLFOX in MC38 tumor-bearing mice, reducing tumor weight significantly compared to control.
-
Animal Model:C57BL/6J WT (6-8 weeks old)[1]
-
Dosage:6 mg/kg
-
Administration:i.v.; 2 doses on days 0 and 3 post-tumor inoculation
-
Result:Reduced B16F10 lung metastasis by >50% compared to control.
Chemical Information
-
CAS No. 3061276-55-6
-
Molecular Weight 276.33
-
Formula C16H20O4
-
SMILES
[H][C@@]12CC[C@@]([C@@]1([H])[C@@H](O)C3=C(C(C=CC3=O)=O)C2(C)C)(C)O
-
Synonyms
IM502
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)